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Fever, the abnormal elevation of central body 
temperature, is a common accompaniment of many clinically 
recognized pathologic states. Among these are infections, 
neoplastic diseases, connective tissue disorders, vascular 
accidents, hemolytic states, drug or chemical reactions, 
and metabolic abnormalities. (11). A mechanism for 
fever production, involving endogenous pyrogen production 
and release by host cells in response to an appropriate 
stimulus, has been proposed on the basis of evidence 
derived from many experimental situations, induced 
primarily in laboratory animals, occasionally in man (4). 
While it has been assumed that the same mechanism is 
involved in the production of fever in the above mentioned 
clinical states, direct evidence for this assumption is 
not extensive. The following work is an attempt to relate 
the fever of Hodgkin’s Disease, a disease often characterized 
by fever, to the proposed mechanism of fever production 





Fever and Neoplastic Disease 
Fevers often complicate the course of patients with 
neoplastic diseases (22, 27, 28). However, while the 
overall incidence of fever in cancer patients is high, 
the significance of the fever to the patient’s course is 
often low (27). Various series reviewed by Boggs and 
Frei (22) and Browder, et. al., (28) covering patients 
with various, primarily internal, solid tumors, showed 
the incidence of fever in these patients to be over >40%, 
Most of these fevers, however, were isolated rises in 
temperature. In only 3% of Briggs’ patients, for 
instance, was the fever deemed to be a prominent 
feature of the patient’s course (27). Furthermore, 
the fever, in most cases, could be ascribed to a coin¬ 
cident infection, often secondary to obstruction caused 
by the tumor. Browder, et. al., in carefully examining 
their series of febrile cancer patients, concluded 
that fever in the absence of infection or obstruction 
was indeed rare. They explained the earlier reports 
of high fever incidence among these patients by the 
high incidence of infection and obstruction amongst 
patients with these cancers, particularly those with 
cancer of the lung or of the gastrointestinal tract. 
In their series, they were able to find only 5^% of 351 
patients who had fever related to their disease, without 
infection or obstruction (28). For the most part, then, 





really a problem of explaining fever in infection. 
There are, however, certain exceptions. One is di¬ 
sease metastatic to the liver. In Browder’s group, the 
incidence of fever in the absence of demonstrable infection 
was two and one half times greater among patients with 
hepatic metastases (28). Earlier, Penster and Klatskin 
had found that 23$ of their febrile patients with carcinoma 
or sarcoma metastatic to the liver had fever unassociated 
with infection (40). 
Other exceptions are those certain neoplasms whose 
presence is often early associated with fever, and often 
without associated infection, obstruction or hepatic 
metastasis. Among these are renal cell carcinoma, (14, 
24, 31, 44, 62, 99), and Hodgkin’s Disease (22, 65, 90, 91). 
In 1929, Creevy reported two cases of fever associated 
with malignant renal tumors, one in which there was no 
metastatic disease, and concluded that, since the fever 
could not be related to necrosis in the tumor nor to 
metastasis, it was due to a product of the abnormal 
metabolism of the tumor tissue (35). Since that time, 
there have been reports placing the incidence of fever 
in patients with this tumor at between ten and twenty 
percent (31, 24, 44). (In a review of 273 cases Berger 
and Sinkoff (14) put the incidence at 16%,) The fever 
is often found in the absence of extensive hemorrhage 
. 
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or necrosis in the tumor, in the absence of metastatic 
disease, without relation to the size of the tumor or the 
extent of local invasion, (62) and, as can be attributed 
by the frequency with which patients with this tumor 
are included amongst series of patients with fever 
of unknown etiology (23, 24, 41, 51, 6l, 79, 83, 99), it 
is often the presenting symptom of the disease. Moreover, 
the fever is so predictably relieved by removal of the 
tumor, that persistence of the fever after operation 
for resection of the primary, or its recurrence at some 
later date, suggest the presence of undiscovered metastatic 
disease (74). 
The fever associated with Hodgkin’s Disease has been 
a particularly intriguing aspect of the clinical picture 
of that disease for over 100 years. Among the first 
patients described by Hodgkin in 1832 was a 25-year-old 
woman who had two intermittent attacks of fever (52). 
In 1858, shortly after the rediscovery of Hodgkin’s work 
by Wilke, Wunderlich described a patient in whom there 
were periodic temperature elevations coincident with 
enlargement of the lymph nodes and spleen (101). In 
1870, Murchison described a six-year-old with a two 
and one half year course of periodic febrile episodes, 
which also were associated with nodal enlargement (32). 
In 1879, Gowers gathered 113 cases of Hodgkin's Disease, 




Twenty-seven had fever which could be related to 
the clinically determined activity of the disease, and 
only thirteen were afebrile or had fever attributable 
to an intercurrent infection. He was the first to 
draw attention to that unusual and interesting pattern of 
relapsing fever which was to be frequently reported in 
the ensuing years and to become widely known as Pel- 
Ebstein-Murchison fever. In this pattern, several days 
of fever which gradually builds in degree, then gradually 
recedes by lysis, not by crisis, is followed by a period 
of normal or subnormal temperatures. He also described 
two other, more common, patterns of fever in these 
patients-continuous, with minimal diurnal variation, and 
intermittent, with evening exacerbations. There followed 
many reports of the more interesting, but rarer, relapsing 
pattern. Osier described a case with intervals of fever 
associated with fluctuating lymph node size, increasing 
with the degree of pyrexia, decreasing during the 
afebrile periods (67). Pel earned his eponym with a 
description of a 25-year-old man who had five episodes of 
fever lasting between ten and 31 days, associated with 
increasing splenic size (78). In 1887, Ebstein reported 
a case, followed for 238 days, during which there were 
nine attacks of fever, of two weeks duration, spaced by 




Taylor reported three more cases with the relapsing 
type of fever, including one gentleman whom he had 
followed through five febrile episodes of seven to thirty 
days duration with afebrile intervals of six to seventeen 
days, who then remained afebrile for four months before 
his eventual death (96). He was the first to point out 
that of the three patterns of fever in Hodgkin’s Disease 
patients as described by Gowers-continuous, intermittent, 
and relapsing, the last was most rare, but when present, 
the most pathognomonic of the disease. In 1911, MacNalty 
gathered together 27 cases of relapsing fever in Hodgkin’s 
Disease reported in the literature and added five of his 
own, using the eponym Pel-Ebstein-Murchison fever to 
describe them (67). 
More recent studies have been concerned with the 
significance of fever in Hodgkin’s Disease patients. 
Lobell, ejt.al, found that 60% of Hodgkin’s Disease 
patients have fever (defined as a single reading greater 
than 103°F or a temperature greater than 100.4° for three 
of five consecutive days) at some point during the course 
of their disease (65). Looking at the biased sample of 
hospitalized patients, Boggs and Frei found that Hodgkin’s 
Disease patients have the highest rate of febrile days to 
total hospitalized days amongst patients with neoplastic 
diseases, and that the fever in these patients was more 
likely to be unassociated with demonstrable infection than 
in patients with other lymphomas, leukemias, or solid tumors (22). 
- zJ 
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In Lobell's study, fever was classified as infection- 
related or disease-related. One half the patients followed 
in their clinic had disease-related fever at some point 
in their course, while only 13% had fever related to 
documented infection. Fever present at the time of 
diagnosis (one third of their patients were in this group) 
was almost exclusively disease-related. Even late in the 
course of the disease, however, a patient with fever was 
more likely to have the fever of Hodgkin's disease than 
to have fever secondary to infection. 
They also found that fever is a bad prognostic in¬ 
dicator independent of certain other bad prognostic signs, 
that the fever thought to be disease-related could not be 
distinguished from the fever of infection by the character 
of the temperature chart alone, and that Pel-Ebstein- 
Murchison fever is indeed rare, being present in only one 





Mechanism of Fever 
Fever is the abnormal elevation of central body 
temperature. It may be brought about by direct activation 
of peripheral mechanisms that increase heat production or 
reduce h at loss, but more often is the result of a central 
alteration of body temperature regulation (32, 33). Body 
temperature is normally maintained relatively constant by 
regulation of heat production and heat loss. This is 
thought to be a funct ±>n of certain centers in the hypo¬ 
thalamus which act in response to peripheral and central 
thermoreceptor input. During fever, regulation of body 
temperature appears to proceed in a normal fashion, but 
at an altered set point (4, 33*100). The mechanism by 
which a new set point is established is not entirely known, 
but it appears, in many animal models, that a common pathway 
is the release of endogenous pyrogen (EP) by cells peri¬ 
pherally, and its action at some point centrally (4). 
Evidence for this pathway consists of demonstration 
of EP production by cells from the periphery, demonstration 
of circulating EP, and demonstration of central effect. In 
many experimental systems various exogenous and endogenous 
pyrogens including Gram negative bacterial endotoxins, gram 
positive bacteria, viruses, antigen-antibody complexes, and 
antigens have been shown to effect the production and 





production (4, 6, 30, 85, 94). Circulating EP has been 
found in many of these systems, including induced strepto- 
coccul and pneumococcal infections, intravenous injections 
of virus, intravenous injection of endotoxin, and intravenous 
injection of antigen or antigen-antibody complexes (4, 9, 
46, 71, 85). Centrally, EP has been shown to induce fever 
upon anterior intrathecal injection of one percent of the 
amount required to produce a similar effect by IV injection, 
and to produce changes in the firing pattern of thermosen¬ 
sitive neurons in this area similar to those seen upon local 
cooling (4, 100). 
It is presently unclear whether endogenous pyrogen 
represents the final common pathway or merely a common 
pathway for elevation of the set point by many varied 
stimuli. Its effect at the hypothalamus may very likely 
be mediated locally by other intra or extra cellular 
messengers, as is the effect of hormones at their target 
tissues (100). 
To summarize, the postulated mechanism of fever pro¬ 
duction involves the interaction of an appropriate stimulus 
with a cell capable of production and release of endogenous 
pyrogen leading to the release of this mediator. EP travel 
via the bloodstream to the anterior hypothalamus where, 
possibly via the release of other substances, it causes a 
change in the pattern of neuron discharge which effects net 





and maintenance of this new termperature level. 
Endogenous Pyrogen 
Endogenous pyrogen is a protein-containing substance 
of molecular weight between ten and twenty thousand (21, 
63, 73). It has been shown to be produced by a number of 
cell types. Blood leukocytes were early recognized as a 
source of EP. In 1948, Beeson first isolated a pyrogen- 
producing substance from rabbit granulocytes and subsequently, 
together with Bennett, in the classic article in the field, 
distinguished th js pyrogen from bacterial endotoxin (11, 12, 
13). They were unable to isolate EP from other cells. Later, 
Gerbrandy, Cranston, and Snell demonstrated that pyrogen 
released human blood was a variable, dependent on the 
granulocyte content of that blood (42). 
However, situations were recognized in which EP 
release by cells other than polymorphonuclear leukocytes 
had to be postulated. Included were fever in agranulocy¬ 
tosis and in inflammatory processes characterized predominantly 
by a mononuclear response such as the granulomatous diseases, 
including Hodgkin’s disease (13). 
It has since been shown that cells other than poly¬ 
morphonuclear leukocytes are endogenous pyrogen producers. 
Mononuclear cells from rabbit lung, and from experimentally 
produced steril exudates, produce EP when suitably activated 





individuals or patients with monocytosis (19), and rabbit 
hepatic Kupfer cells (36) have been shown to release EP 
in vitro when activated. The presence of pyrogen in 
tissue monocytes may be the explanation for the pyrogenic 
activity of saline extracts from normal rabbit tissues 
(10, 93a). Circulating human eosinophils have recently 
been shown to release EP when activated in vitro by phag¬ 
ocytosis or bacterial endotoxin (69). Studies by Snell 
and Atkins, by Root, et_. al, and by Kammermeyer, et_. al, 
have failed to demonstrate EP release by circulating, 
lymph node, or cultured lymphocytes (4, 56, 84). Lympho¬ 
cytes have, however, been shown to produce a substance 
capable of provoking EP release from competent cells (7). 
Endogenous pyrogen production by PMN leukocytes only 
occurs following cell stimulation (17, 74, 55). Although 
the exudate granulocyte has been found to be spontaneously 
active, an activator has been isolated from the exudate 
fluid which is presumably res pnsible (70). Activation of 
PMN leukocytes may follow stimulation by endotoxin, 
phagocytosis, antigen-antibody complexes in the presence 
of complement, or, perhaps, by lymphokine mediator (3, 7, 34, 
^2, 74, 94, 100). An early, essential response of the cell 
to stimulation is new RNA and protein synthesis. Measurable 
EP release begins at about two hours after activation 







suppressed by agents that block protein synthesis or 
glycolytic pathways only if such agents are added 
during the initial two-hour period after the activation 
(17, 7^). 
Blood and tissue monocytes appear to behave differently 
in several respects (5, 15, 19). They release 4-10 times 
the amount of pyrogen for the same stimulus as do PMN 
leukocytes and they continue pyrogen release longer after 
activation, perhaps 48-72 hours. Also, throughout this 
period, pyrogen production by these cells can be suppressed 
by inhibitors of protein synthesis. 
Mechanism of Hypersensitivity Fever 
Clinical association between fever and hypersensitivity 
reaction has been long recognized, as in conditions such 
as serum sickness and drug reactions (4). Experimentally, 
injection of an antigen into a sensitized animal will result 
in fever (71). Serum antibody appears to be essential to 
this response. Wolff’s group has suggested that it is the 
antigen-antibody complex which is the stimulus to endogenous 
pyrogen production in this situation, as antigen-antibody 
complexes prepared in vitro produced fever when injected into 
unsensitized animals (71, 85). Attempts to produce EP 
release by blood cells i_n vitro using antigen-antibody 
complexes has usually been unsuccessful. Atkins failed to 
induce EP production using complexes of bovine gamma globulin 
* 
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(BGG) and rabbit anti-BGG prepared in antigen excess (7). 
In other experiments, when the benzyl penicilloyl nucleus 
of penicillin was incubated with serum and cells from 
sensitized animals, Atkins and Chusid were able to demonstrate 
EP release. The exact nature of this hypersensitivity 
reaction was not defined, however (30). 
Fever production has also been studies in systems of 
delayed hypersensitivity. Injection of Old Tuberculin causes 
fever in tuberculin sensitive rabbits, and this response 
can be transferred to non-sensitized rabbits by mononuclear 
cells as well as by serum (4, 50, 50a). Blood leukocytes 
and tissue macrophages from tuberculin-sensitized animals 
release EP upon in vitro incubation with antigen (5, 8). 
This suggests that antigen has a direct effect upon poly¬ 
morphonuclear and mononuclear cells, inducing EP release. 
Recently, using another model Atkins, et_. al, demon¬ 
strated a role for lymphocytes as mediators leading to 
endogenous pyrogen release in a system of delayed hyper¬ 
sensitivity. Rabbits were immunized to dinitrophenol (DNP)- 
conjugated bovine serum albumin, to DNP-bovine gamma 
globulin, or to human serum albumin. Upon incubation of 
lymph node lymphocytes obtained from these sensitized animals 
with the appropriate antigen, a substance, perhaps a lympho- 
kine was released which, while not itself pyrogenic, induced 







Clinical Fever and Endogenous Pyrogens 
Although the mechanisms of EP production discussed 
above have been postulated to account for clinical fever 
in man, there is little experimental evidence for this 
hypothesis (4). Such evidence ought to include (1.) 
demonstration of endogenous pyrogen production by human 
cells in response to appropriate stimuli, (2.) isolation 
of EP from patients with diseases characterized by fever, 
(3.) detection of EP in the circulation in association with 
fever, and (4.) induction of fever by EP administration. 
Several human cell types have been shown to produce 
endogenous pyrogens in vitro. Polymorphonuclear leukocytes, 
blood monocytes, eosinophils, and spleen and lymph node 
mononuclear cells are all capable of EP release if suitably 
stimulated by phagocytosis (16, 19, 69, 74). Spleen and 
lymph node cells, predominantly mononuclear, are occasionally 
"spontaneously" active in vitro, unlike the other cell types 
which require activation (16). In addition, cell suspensions 
from renal cell carcinomas have been found, by Bodel, to be 
capable of EP release during in vitro incubation (15). 
Several studies have demonstrated the presence of an 
endogenous pyrogen in fluids obtained from patients, although 
not always febrile ones. In 1962, Snell reported the presence 
of a pyrogen, with properties characteristic of EP, in 






effusions (93). A similar substance was not present in 
transudates from patients in congestive heart failure. 
However, there was no correlation between EP isolation 
and the presence of fever in the patient. Bodel and 
Hollingsworth reported that a pyrogen, active in rabbits, 
was present in the joint fluids of patients with such 
diseases as rheumatoid arthritis, acute rheumatic fever, 
pseudogout, Reiter's syndrome, and metastatic carcinoma 
(20). Sokal and Shimaoka have demonstrated a pyrogen in 
the urine of febrile patients with Hodgkin's disease and 
another febrile patient, not present in the urine of normal 
controls (95). Finally, Rawlins, et. al, found a similar 
pyrogen in renal carcinoma tissue (82). 
The a arch for circulating endogenous pyrogen in 
clinical febrile states has been uniformly unsuccessful. 
Snell was unable to demonstrate circulating EP by re¬ 
infusion of plasma taken from patient febrile with various 
infections (92). Bouruncle and Doan tried reinfusing 500 
ml. of whole blood from patients febrile to 103° F with 
periodic fever, and, similarly, failed to induce fever in 
these same patients, when they had become afebrile (25). 
Sokal and Shimaoka were unable to produce fever by 
reinfusion of plasma obtained from febrile Hodgkin's disease 
patients (95). Cranston, using malaria patients, was 




but not the plasma; this result seems more likely 
due to the host response to altered cells, or to the 
parasite, than to a preformed pyrogen (32). 
Since Bodel and Atkins have shown that human 
endogenous pyrogen can be assayed in rabbits (18), the 
necessity for reinfusion studies has been eliminated, 
but the results have not changed. Greisman, et.al, using 
a rabbit assay that permitted pyrogen testing up to 
20 ml. of human plasma in rabbits, after absorbing out 
the hemagglutinins, were unable to demonstrate a pyrogen 
in plasma drawn from febrile (104° - 105°F) patients with 
Rocky Mountain Spotted Fever (147). 
Even when febrile reactions have been experimentally 
induced in humans, circulating EP has not been found. 
Until recently there was only one encouraging result 
reported. Whole blood taken from a volunteer at the 
height of a fever (38.2°C) caused by an injection of heat 
killed E. coli, induced an early (20 minute onset) fever 
in a second subject of the same blood group. Subsequently 
attempts have been made to find circulating EP by cross 
infusion or reinfusion of cells or plasma from subjects 
febrile due to EP infusion, 11-keto-pregnanolone infusion 
and S. typhosa endotoxin injection (43, 47, 59* 8l). 





Most recently, Greisman and Hornick have produced an 
early (45 minute onset, 90 minute peak) temperature elevation 
by infusion of 750 ml. of plasma pooled from three donors 
made febrile to 102°P by S. typhosa endotoxin (47). 
While the proposed mechanism for fever production via 
endogenous pyrogen release requires that EP be present, at 
some time in circulating blood, the failure to demonstrate 
it there does not necessarily imply that it is never present. 
Perhaps the failure to demonstrate it in these many experi¬ 
mental and clinical situations relates to the amount of 
pyrogen present in the fluid sampled, its distribution in 
the sample with respect to protein binding, the time of 
sampling with respect to fever present in the donor, or the 
failure of the assay method to reproduce a physiologic 
method of presentation of the pyrogen to its receptor at 
the hypothalamus. 
Cranston’s group showed that endogenous pyrogen 
produces fever in man when they infused EP prepared by 
endotoxin stimulation of blood cells (34, 42, 8l). 
Fever in Malignant Disease 
The relation between the fever of malignant disease 
and the proposed mechanism of fever discussed above, is 
largely unknown. Clinically, most fevers in cancer patients 
• 
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are related to infection (28). Thus inflammation, necrosis, 
and immune reaction may all be present and all of these 
processes have been experimentally linked to EP production 
(4, 53). However, there are some tumors, discussed pre¬ 
viously, which appear to be more frequently associated with 
fever in the absence of demonstrable infection. These 
tumors, which include renal cell carcinoma and Hodgkin’s 
disease have received particular attention because of the 
possibility that fever in these states might be definitively 
associated with endogenous pyrogen. 
Rawlins, e_t al,detected an endogenous pyrogen in 
tumor extracts from two febrile patients with renal cell 
carcinoma (82). They found no EP in normal kidney, in par¬ 
tially necrotic tumor tissue from one afebrile patient with 
renal cell carcinoma, or produced by circulating leukocytes 
from the febrile patients. Bodel has found that cells from 
renal carcinomas, which have not been previously irradiated, 
spontaneously release EP upon incubation in tissue culture 
medium containing patient serum, whereas cells from irradi¬ 
ated tumors, even when necrotic, and cells from adjacent 
normal kidney produce little or none (15). This in vitro 
EP release has not, however, correlated with the presence 
of fever in the patient. It appears that there are other 
factors beyond capacity for EP release which determine 
whether the capacity for EP release becomes manifest as 
. 
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fever in the patient. Activation may be one important 
factor, as the cells may require a specific stimulating event 
in vivo. Other factors may be rate of absorption into 
the circulation, suppression of EP production in vivo, 
inactivation of the pyrogen itself in the circulation or 
at the target tissue, or modification of the target tissue’s 
response to the EP stimulation. 
Since renal cell carcinoma has been widely implicated 
in other paraneoplastic syndromes related to the elaboration 
of a protein or peptide by tumor tissue, it may be that the 
tumor cells themselves are synthesizing EP. However, the 
pyrogen may be from inflammatory cells present in the tissue, 
although, if such were the case, one would expect EP 
production from cells in the previously irradiated kidney 
tumor as well. 
In one case of neuroblastoma, which is also frequently 
associated with fever (39)> Chassin and Bodel were unable 
to demonstrate EP release after 72 hour incubation of tumor 
cells from a febrile patient (19a). However, this tumor, 
which, like the pheochromocytoma, makes vasoactive amines, 
may cause fever by vasoconstriction and decreased heat loss, 
thus altering the efferent, rather than the afferent limb 
of the termperature regulatory process. 
The first observation concerning an endogenous pyrogen 
in Hodgkin's disease patients was made by Sokal and Shimaoka 






circulating EP in febrile patients they were unable to 
demonstrate EP in the plasma of febrile Hodgkin’s disease 
patients. They had attempted this by reinfusion of 
autologous plasma to these patients when afebrile. However, 
in examining urine concentrates, they found a pyrogen 
capable of causing fever in rabbits. Concentrates 
representing 0.03 - 1,0% of a twenty four hour urine 
collection from six of seven febrile patients caused 
fever in rabbits, whereas none of four concentrates from 
normal controls caused fever. They did not examine the 
urine of afebrile Hodgkin's patients. A concentrate from 
a febrile, non-Hodgkin’s diseased patient behaved similarly 
to that from the febrile Hodgkin’s patients. In each case 
the fever curve obtained was characteristic of that caused 
by EP, with a rapid onset after injection, and a peak at 
one hour. There was suppression but not elimination of 
the fever when the material was tested in endotoxin- 
tolerant rabbits; repeated injections of the pyrogen daily 
for one month caused no tolerance. 
In 1971, Young and Hodas described, in an abstract, 
the isolation of a protein from the urine of febrile 
Hodgkin's disease patients which was not present in the 
urine of afebrile patients with the disease (101). This 
material behaves, under electrophoresis, like a protein 










plasma of febrile Hodgkin’s patients. It has a molecular 
weight of 15,000 similar to that described for endogenous 
pyrogen (21, 63, 73), but also has an isoelectric point 
of 10, which is unlike any described for EP. The isoelectric 
point for human EP is about 7.0 (73)• It is unclear 
whether this protein can be related to EP, and its signi¬ 
ficance remains obscure in the absence of any demonstration 
of pyrogenicity. 
Most recently, Bodel has examined the capacity of 
various tissues from patients with Hodgkin’s disease to 
produce endogenous pyrogen (15, 16). Blood leukocytes 
from these patients were indistinguishable from normal 
donor’s leukocytes in that they did not spontaneously 
produce pyrogen, but invariably did so when activated by 
phagocytosis. However, lymph node and spleen cells from 
patients with lymphomas released EP upon in vitro incubation 
in tissue culture medium. Spleen cells from patients 
with non-malignant splenomegaly did not release EP spon¬ 
taneously, but did so in response to phagocytosis. Since 
production of EP continued for 48-72 hours in lymph node 
suspensions and since this production was sensitive to 
inhibition by puromycin, mononuclear cells appear to be 
responsible for pyrogen production in this tissue. In 
spleen cells, the production of pyrogen did not correlate 





however since cycloheximide was only partially inhibitory, 
both polymorphonuclear and mononuclear leukocytes may 
contribute to EP release by this tissue. The production 
of EP did not correlate with presence of clinical fever 
in the patient, nor with pathological evidence of tissue 




Hypersensitivity and the Pathogenesis of Hodgkin* s Disease 
The histology of Hodgkin's disease is such that 
there has long been question as to whether the process is 
neoplastic or granulomatous (58). The Jackson and Parker 
classification graded the histology from paragranuloma 
to sarcoma with the prognosis being better for the para- 
granulomatous type than for the more frankly malignant 
sarcomatous (54). The Lukes and Butler classification 
takes account of the different histories of the patients 
with different histologic lesions in its progression from a 
lymphocyte predominance type with a better prognosis to the 
lymphocyte depletion type with a worse one (66). It appears 
that the lymphocytes may represent a reactive element in the 
tissue whose presence can be correlated with a longer sur¬ 
vival. The cells predominating in the lymphocyte depleted 
lesion, the reticulum cells and the Reed-Sternberg cells, 
appear to be proliferative elements, perhaps the neoplastic 
cell line whose predominance is correlated with a poorer 
survival. The suggestion is that the disease represents a 
mixed reactive-proliferative state, that the reactive 
element is the earlier one, and that it in some way may lead 
to or be replaced by the later proliferative state. 






between Hodgkin's disease and a graft versus host reaction 
(58, 97, 29). Smithers and Kaplan, in 1959, first pro¬ 
posed that the proliferative elements were lymphocytes 
that had lost some of their antigenic determinants, and 
therefore recognized normal host cells as foreign, leading 
to a reaction against the host and their own proliferation 
(58). Tyler, in i960, made a similar proposal (97). Since 
then Schwartz and his colleagues, as well as others, have 
provided a strong experimental model for lymphomas resulting 
from chronic graft versus host disease (2, 64, 87, 88, 89). 
The requirements for producing the disease are an 
immunocompetent graft, a host antigen recognized as foreign, 
and an immunoincompetent host. In experimental models, 
the first is provided by a parental spleen cell implantation, 
the second by the antigens of the other parent strain ex¬ 
pressed by the hybrid, and the third by a tolerant F^ 
hybrid or an immunosuppressed adult animal. The result is 
an early lymphoid reaction and late lymphocyte depletion, 
repopulation of the area by plasma cells and reticulum cells, 
and, in a certain percentage of cases, a proliferative 
reticulum cell or plasma cell population. There is also 
splenomegaly and lymphadenopathy clinically, impaired sys¬ 
temic immune responsiveness, and, in some models, auto¬ 





An interesting finding, by the Schwartz group, is 
that the proliferative cells are not of the immunocom¬ 
petent parent line, but of the immunoincompetent host line 
(89). Apparently the host cells are stimulated by the 
immunocompetent cells, or by the damage they cause, to 
undergo neoplastic transformation. This may be by mutation, 
such as if the products of lymphocyte breakdown cause 
mutation that leads to a loss of proliferative regulation. 
It also may be that the immunodepression caused by the graft 
versus host disease allows the proliferation of cells 
containing a viral oncogene. These cells could be of host 
origin, but would also perhaps be recognizable by a viral- 
associated antigen which they might display. 
Recently, Order, et_ al, demonstrated by immunofluores¬ 
cence such a tumor-associated antigen in Hodgkin’s disease 
tissue, not present in adjacent normal tissue (75, 77). 
Also, using immunoelectrophoresis they were able to demon¬ 
strate two antigens common to 18 of 19 Hodgkin's disease 
spleens, two of four suspicious spleens, and four of seven 
pathologically negative spleens, but in increased concentra¬ 
tion in the positive spleens (75). This further piece of 
evidence suggested to them a hypothesis which they proposed 
for the pathogenesis of Hodgkin's disease (76). In it, 
host T cells are infected by a virus leading to a changed 
. 
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suface antigen (26) - perhaps the tumor associated antigen 
which they have found. If the transformed cell also 
manages to maintain host tolerance, a graft versus host 
reaction might ensue, leading first to lymphocyte reaction 
and, in time, to lymphocyte depletion with repopulation by 
plasma cells and proliferating reticulum cells and their 
end stage Reed-Sternberg cells. Because of T cell involve¬ 
ment in the graft versus host reaction, there would be 
systemic anergy, a condition frequently associated with 
active Hodgkin’s disease (1). 
If their hypothesis is correct, then a further con¬ 
sequence would be that in the presence of an ongoing cell 
mediated immune reaction, such as the graft versus host 
reaction proposed here, at least for the early part of the 
pathogenesis, there would be T cell blast transformation 
and lymphokine production. If one of these lymphokines is 
a factor which activates cells competent to produce 
endogenous pyrogen to do so, as proposed by Atkins (7)» 
then we might expect to demonstrate such a lymphokine in 




The objective of the research discussed below is to 
investigate the release of pyrogen in vitro by cells from 
patients with Hodgkin's disease. The three separate aims 
of the three studies which make up this work are outlined 
below, based on information discussed in the introduction. 
I. Comparison of spontaneous pyrogen release in vitro by 
lymphoid tissue from patients with Hodgkin's disease with 
that by lymphoid tissue from patients without Hodgkin's 
disease. 
As noted, endogenous pyrogen release is a well estab¬ 
lished pathway in the mechanism of fever production in a 
number of experimental models, but evidence for this path¬ 
way in clinical fever is scanty (4). Second, fever commonly 
accompanies Hodgkin's disease in the absence of demonstrable 
infection (65). Third, EP release in vitro has been demon¬ 
strated for cells from another tumor commonly associated 
with fever - renal cell carcinoma, and a pyrogen has been 
found in the tissue of this tumor (15, 82). Finally, EP 
release in vitro has been demonstrated for lymphoid tissue 
from patients with malignant lymphomas (16). 
In view of this, the first objective of these experiments 




tissue of patients with Hodgkin's disease with that by 
cells from lymphoid tissue of patients with other disorders. 
II. Investigation of the effect of serum on pyrogen release 
by lymphoid tissue in vitro. 
The lack of correlation between demonstrable pyrogen 
release by tissues in vitro and the presence of clinical 
fever in the patient has been noted above (15* 16). One 
explanation for this is that the cells have not been acti¬ 
vated in vivo to releaa €EP. Alternatively certain factors 
may be acting in vivo to suppress EP production and re¬ 
lease. In order to investigate the latter possibility, 
the effect of different concentrations 
of sera upon in vitro EP release was examined. 
III. Studies of the action of lymphocytes on induction of 
pyrogen release by blood leukocytes. 
As discussed above, Hodgkin's disease may represent a 
proliferative response to a foreign antigen or to a self 
antigen which has been recognized as foreign by abnormal 
lymphocytes (76, 58, 97). Also, sensitized lymphocytes 
have been shown to release a substance, perhaps a lympho- 
kine, which may activate normal leukocytes to produce endo¬ 
genous pyrogen, when these lymphocytes are themselves acti¬ 
vated by the sensitizing antigen (3, 7). Release of such a 
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substance by activated or altered lymphocytes in spleen 
and lymph nodes from patients with Hodgkin’s disease 
could explain the "spontaneous” release of pyrogen 
characteristic of these tissues, through interaction of 
these immunocompetent cells with tissue polymorphonuclear 
or mononuclear cells capable of endogenous pyrogen production. 
To examine this hypothesis, lymphocytes from spleen and 
lymph node tissue were incubated with blood leukocytes in 
an attempt to induce a pyrogen release. 
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MATERIALS AND METHODS 
I. Sterile pyrogen free technique. All materials, glassware, 
and reagents used in these experiments were sterile and pyrogen 
free. Metalware, glassware, and glass wood were sterilized in 
hot air ovens at l8o° C for 2 hours. Solutions were autoclaved 
at 15 p.s.i. for 90 minutes. Alicuots were incubated in 
thioglycollate broth and tested for pyrogenicity in rabbits. 
Reagents not prepared in this laboratory were pyrogen tested 
before use, or were obtained sterile and pyrogen free. 
II. Reagents. Tissue culture medium (TCM). Auto POW Eagle 
minimal essential medium (Flow Laboratories, Rockville, 
Maryland) was prepared as follows: 9-39 grams Auto POW 
medium was made to one liter with sterile water. The 
solution was autoclaved 20 minutes at 15 p.s.i. pH was 
adjusted to 7.4 by the addition of sodium bicarbonate 
solution, and penicillin-streptomycin (Grand Island 
Biological, Grand Island, N.Y.) was added to 5 units 
penicillin and 5 micrograms streptomycin per ml. of tissue 
culture medium. Just before use, heparin (Liquemin Sodium, 
Organon, W. Orange, New Jersey) was added to tissue culture 
medium to a final concentration of 10 units per ml. 
Modified Krebs-Ringer-Phosphate buffer (KRP buffer). A 1.43% 
Na2HP0i| solution was filtered and adjusted to jH 7.4 with HC1. 
A base prepared of 40 ml. of 1.15% KC1, 6ml. of 1.22$ CaC^ and 
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2 ml. 3*82$ MgSOh 7H2O in sufficient saline to bring the total 
volume to one liter was autoclaved for 90 minutes. 105 parts 
base and 20 parts phosphate solution and 10 units/lml. heparin 
were combined just before use. 
Human serum albumin. A 25% salt poor albumin solution 
(American National Red Cross) was added to TCM or to KRP 
buffer as described below, for the isolation of lympho¬ 
cytes by the column procedure. 
Heat killed Staphylococcus albus. A strain of S. albus was 
maintained on agar. Cells from an 18 hour broth culture of 
the bacteria were washed with saline, resuspended in saline 
and autoclaved for 20 minutes. They were stored at -18°C 
Q 
in a suspension of approximately 5x10 bacterial cells/ml. 
estimated by comparison of optical density with a standard 
curve. 
III. Pyrogen Assay. Pyrogen testing was carried out in 
adult New Zealand White rabbits (Montowese Rabbit Farms, 
North Haven, Conn.). Animals were boxed for nine hour 
intervals in a constant temperature room (l8.3°C) and 
termperatures were measured at 15 minute intervals with 
Telethermometer (Yellow Springs Instrument Co., Yellow 
Springs, Ohio) or continuously with automatic temperature 
recording equipment (Rustrak Gulton Industries, Manchester, 
New Hampshire) via rectal thermoprobe. Rabbits were not 
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used if a stable baseline temperature was not present 
for 30 minutes prior to each injection. Each rabbit was 
used for only 5 consecutive calendar days to prevent inter¬ 
ference with the assay due to hypersensitivity to human 
serum constituents. 
"Dose" (see below) refers to the number of cells 
incubated in the supernate to be assayed. Supernates to 
be assayed were injected via the ear vein. In most experi¬ 
ments the same rabbits received both control and experimental 
supernates, and the same supernate was injected into more 
than one rabbit, whenever sufficient material was available. 
The maximum temperature elevation occurring between 30 
and 75 minutes after injection was charted. 
IV. Preparation of tissues. Spleens and lymph nodes were 
obtained in saline directly from the sterile field at 
operation. The tissues were weighed, then minced in 
tissue culture medium, and the spleens additionally screened 
through wire mesh. The suspensions were cultured in 
thioglycollate broth, a free cell count was determined 
by coulter electronic particle counter (Coulter Electronics, 
Hialeah, Fla.) and a cover glass smear was made to be 
stained with Wright’s stain for differential count. 
V. Preparation of normal leukocytes. Venous blood was 
withdrawn into a heparinized (lOu/ml) syringe from normal 
, 
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volunteers, or, in some cases from patients. It was allowed 
to sediment for one hour, after which time the leukocyte 
rich plasma was removed and centrifuged at 500g for 15 
minutes. The cells were resuspended in TCM (with heparin 
lOu/ml) counted by means of a coulter particle counter, 
7 
and added to the incubation flasks to provide 3-7x10 cells 
per white cell dose. A cover slip slide differential was 
performed from blood smears after staining with Wright’s 
stain. 
VI. Column separation of lymphocytes. Size #20 glass 
columns (Kontes Glass Co., Vineland, N.J.) were filled with 
glasswool under saline using sterile techniques. The 
eluate saline was cultured. A solution of modified Krebs- 
Ringer-Phosphates buffer containing heparin (lOu/ml) and 
human serum albumin (0.75-1.5$) was run onto the column 
and was allowed to equilibrate at 37°C. 
A portion of the spleen cell suspension was strained 
through several layers of sterile gauze and the concentration 
7 
adjusted to approximately 2x10 cells per ml. in TCM with 
lOu/ml. heparin and 1.5$ human serum albumin. 
The spleen cell suspension was run onto the column 
rapidly, allowed to stand 30-40 minutes at 37°C, and eluted 
with twice the volume of KRP buffer containing heparin and 
albumin. The eluate was centrifuged at 500g for 15 minutes, 
and the cell button resuspended in tissue culture medium 
g 
to be added to the incubation flasks at approximately 2x10 
. 
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cells per dose of lymphocytes. An aliquot was cultured 
and a Wright's stained cover slip smear was made for 
differential count. 
VII. Incubations. 
A. Incubation for spontaneous pyrogen release. Tissue cell 
suspensions were incubated to provide 0.5-1.8 g. spleen, 
wet weight (1.3-7.0x10^ free cells) or 50-333 mg. lymph 
node (wet weight), per dose. Each dose was suspended in 
4-5 ml TCM with 10-15# serum, in an Erlenmeyer flask. The 
flasks were flushed with 5# CO2 in air (Matheson Gas 
Products), sealed with Parafilm over a cotton plug, and 
incubated overnight in a Dubnoff shaker at 37°C. They 
were resuspended after 24 hours, and in some cases, 48 
hours, as follows. The contents of the flasks were 
centrifuged at 600 g for 15 minutes and the supernatants 
saved. The cell clump was resuspended and reincubated 
as on the first day. The supernatant of the first cen¬ 
trifugation was then recentrifuged at 2000g for 30 minutes, 
and the supernate of this spin was stored at 4°c for 1-7 days 
or at -l8°C for 1-3 weeks until it could be tested for 
pyrogenic activity. 
B. Activation with Staphylococci. One flask was usually 




C. Serum Studies. Suspensions were made up as above 
except that serum concentration was varied between 
10-15# and 30-35# with patient and/or normal 0- homologous 
serum. 
D. Activation by lymphocytes. Spleen. Incubations 
with lymphocyte preparations were done using the cells 
eluted from the column as described. Incubation sus¬ 
pensions were made up as above with 10-15# serum in TCM 
Q 
to a total volume of 4-5 ml. per injected dose. 1-2x10 
column cells were incubated alone as one lymphocyte 
dose, or with two leukocyte doses (at 3-5x10? WBC/dose). 
In some cases the leukocytes were added to the lymphocyte 
suspension at the outset, in others after lymphocytes 
had incubated alone for 24 hours. 
Lymph node. One lymph node does (50-250 mg.) was used 
in place of spleen column lymphocytes. Otherwise the 





IA. Spontaneous endogenous pyrogen release by splenic 
tissue in vitro. 
Thirteen spleen specimens from patients with 
Hodgkin’s disease (HD) and twelve from patients with 
diseases other than Hodgkin’s disease (non-Hodgkin’s 
disease, NHD) were processed. The patients in the 
NHD group included six with idiopathic thrombocytopenic 
purpura (ITP), three with non-Hodgkin’s lymphoma (NHL), 
one with autoimmune thrombocytopenia secondary to systemic 
lupus erythematosus, one with a splenic artery aneurysm, 
and one with a traumatic ruptured spleen. 
The specimens were prepared and incubated as described 
in the Materials and Methods section. Briefly, the cells 
were suspended in tissue culture medium (TCM) with 10-15# 
serum and resuspended after 24 hours for a second 24 hours. 
Supernates from each incubation were tested for pyrogen 
by injection into rabbits. An example of a typical fever 
curve obtained is shown in Figure I. This has the 
characteristic short latency, early peak ( { 90 minutes), 
and rapid fall to normal characteristic of EP fever. For 
each injection, peak termperature elevation occurring 
within 90 minutes was determined. Since the relation between 




linear up to 0.8° C. elevation (84), the mean peak tempera¬ 
ture elevation for any group of supernates was considered 
the measure of pyrogen for that group. 
The results of comparison of pyrogen release by 
spleen cells from patients with various diseases is shown 
in Figure II. The mean peak temperature elevation produced 
by supernates from the first 24 hour incubation is 0.40±.04° 
C for the HD group, 0.13*.02° C for the NHL group, 0.20^.04° 
C for the ITP plus lupus group, and 0.39*.10° C for the 
other two. While results from the HD group and the last, 
and presumably most normal spleen group are similar, the 
last group is heavily weighted by the pyrogen production 
by cells from the ruptured spleen. This patient had been 
observed for two days properatively, and clinically demon¬ 
strated inflammation. Over all, comparing the HD group 
with the entire NHD group (Fig. 3)s there is a significant 
difference (p £ .02 by t test for difference of means) be¬ 
tween the amount of pyrogen released during a first incuba¬ 
tion from tissues in the two groups. 
To look at this in a different way, the mean peak 
temperature elevation produced by injection of the super- 
nate from the first incubation, was examined for each spleen; 
when the mean elevation was greater than 0.3° C, the tissue 
was considered "positive" for pyrogen release. Nine of the 
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thirteen spleens in the HD group were positive, and only 
three of twelve in the NHD group were positive. The 
number of cells and weight of tissue per dose are not 
significantly different in the two groups (Table I). 
Similarly the response to a phagocytic stimulus was not 
different, as all specimens in each group produced pyrogen 
in response to incubation with heat-killed staphylococci. 
Differential counts were performed on a suspension 
from each spleen, and the percentage of pyrogen producing 
cells-polymorphonuclear leukocytes, eosinophils, and large 
monocytic cells-was compared. There were 27-2% of these 
cells in the suspensions from the HD group, and 25-2$ in 
the suspensions from the NHD group. Thus there is no sig¬ 
nificant difference between the two groups with respect to 
the proportion of pyrogen producing cells. 
The results of assay of spontaneous pyrogen release 
during the second 24 hours is also shown in Figures II and 
III. Pyrogen release was greater in all groups during the 
second period than during the first. The difference in 
pyrogen production between the HD group and the NHD group 
during this incubation is not significant. This result 
suggests that there has been a ’’warming up” to pyrogen re¬ 
lease, a process in which the spleen cell suspensions from 
the HD patients had, for some reason, a head start. It 

39 
may also indicate a greater capacity for release, since 
the total production is therefore, greater in the HD 
group. 
In the previous series of Bodel, spontaneous pyrogen 
release by spleen cells did not correlate with histological 
evidence of pathological involvement of the tissue. In 
this series only 20$ of the spleens from patients with HD 
are positive for disease as determined by the surgical 
pathologist. This number is not large enough to allow 
division of the H D group into two subgroups (one with, 
and one without, clear-cut pathological involvement) 
for further analysis. 
. 
. 
Figure Is Typical Fever Curve. 
The temperature response in one rabbit to injection 
8 
(at arrow) of supernate from incubation of one dose (3»5 x 10 
cells) of spleen cells from a patient with Hodgkin's 







Figure II: Spontaneous Pyrogen Release by Spleen Cells 
in vitro: I. 
In this and subsequent figures, bars represent mean 
peak temperature elevations, - standard error of the mean, 
produced by injection of supernate from the incubation of 
tissue cells. In experiments with spleen, each dose of 
supernate, injected into a single rabbit, was derived from 
8 
an average of 3.5 x 10 cells; in experiements with lymph 
nodes, from an average of 170 mg. (wet weight) of lymph 
node tissue. The numbers in parentheses refer to the 
number of supernate doses assayed in each group. The 
following abbreviations are used: HD, tissue from patients with 
Hodgkin’s disease; NHL, tissue from patients with non- 
Hodgkin’s lymphoma; ITP, tissue from patients with idio¬ 
pathic thrombocytopenic purpura; SLE, tissue from patients 
with systemic lupus erythematosus. Day 1 refers to the 
first 24 hour incubation. Day 2, to the second. In this 
figure ’’other” refers to one tissue from a patient with 
traumatic ruptured spleen and one from a patient with a 
splenic artery aneurysm. Pyrogen release is presented 
for Day 1 and Day 2 incubations for the four different groups 
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Figure III* Spontaneous Pyrogen Release by Spleen Cells 
in vitro •. II. 
In this and subsequent figures, NHD refers to tissue 
from patients with diseases other than Hodgkin’s disease. 
In comparisons only differences significant to p < 0.2 
by t test for means are noted. In this figure, mean peak 
temperature elevations following injection of supernates 
are compared for HD and NHD groups of tissues, during both 



























Table I : Comparison of spleen cell populations between 
HD end NHD groups* 
HD NHD 
■ Wet weight(g) 
per dose 1.04±.07 1.01-.06 
Free cells(xlO^) 
per dose 3.52-.70 3.57^.36 
Non-lynxohocyte 
cells~(/S) 2.7±2 25-2 
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IB. Spontaneous endogenous pyrogen release by lymph node 
tissue in vitro. 
Nodes were obtained from four patients with Hodgkin’s 
disease, three patients with non-Hodgkin’s lymphoma, three 
patients with metastatic carcinoma, and five with adeno¬ 
pathy with a reactive histology. This latter group 
included pathological diagnoses of lymphoid hyperplasia, 
sinus histiocytosis, and in one case, caseating granuloma 
consistent with lymphogranuloma venereum. The tissues were 
minced, and the cells incubated in TCM containing 10 or 
30# serum for successive 24 hour periods, as described in 
Materials and Methods. Supernatants were injected into 
rabbits to determine the presence of endogenous pyrogen. 
The results of pyrogen testing are shown in Figure IV. 
Clearly, only small amounts of pyrogen were released by 
cells from any of the groups, during a first or second 
incubation. The small release may be due to inadequate 
amounts of tissue per dose used in this system. The diffi¬ 
culty in obtaining larger lymph node specimens made this 
dose a necessity. There is no significant difference 
between pyrogen release by HD tissue compared with that by 
NHD tissue (Fig. V). Neither is there any significant 
difference between the two groups with respect to average 
amount of tissue per dose, being 171-41 mg# in the HD 
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group, and 173-21 in the NHD group. Estimates of cell 
types from differential smears were very difficult to 
perform in these experiments, because the cells appeared 
unusually fragile. However, the smears appeared com¬ 
parable between the two groups. In only one case (a 
carcinoma node) were there more than 5% polymorphonuclear 
leukocytes in a smear. 

Figure IV: Spontaneous Pyrogen Release by Lymph Node 
Cells in vitro: I. 
Pyrogen release is presented for Day 1 and Day 2 in¬ 
cubations for the four different groups of lymph node 
tissues. Reactive refers to lymph node tissue displaying 
a reactive histology (see text), Ca to tissue from patient 
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Figure Vi Spontaneous Pyrogen Release by Lymph Node 
Cells in vitro t II. 
Mean peak temperature elevation following injection 
of supemates from incubations of lymph node from pa¬ 
tients with Hodgkin's disease is compared with that from 
patients with other diseases. Data for both a first and 































IIA. Serum studies: the effect of varied serum 
concentration upon spontaneous EP release 
by lymphoid tissue in vitro. 
Since, in Bodel’s work, spontaneous endogenous 
pyrogen release has not been correlated with fever in the 
patient, it is possible that factors acting in vivo may 
modify the capacity of these cells for EP release. One 
of these factors may be a serum inhibitor. In the incuba¬ 
tions in Bodel’s series, the serum concentration in the 
incubation mixture was 10-15$. In order to investigate 
the possible effect of higher serum concentration on in 
vitro EP release, cells from lymph nodes and spleens were 
incubated in TCM with 10-15$ serum and 30-35$ serum. 
Serum was either autologous or homologous, from a normal 
0- donor, but for each individual specimen, the same 
serum was used at both concentrations. Incubation was 
carried out for two successive 24 hour periods. 
Because of the small number of nodes (4) in this 
study, and the lack of significant difference between 
pyrogen release by the nodes during a first or second 
incubation (Fig. IV), pyrogenic responses to supernates 
from incubation on day one and day two were combined in 
determining an average. Therefore, Figure VI shows mean 




Lymph node cells from Hodgkin’s disease patients 
made less pyrogen when incubated with 30$ serum than when 
incubated with 10$ serum. However, because of the 
small number of supernates assayed, this apparent difference 
is not statistically significant (p ^ .2). There is no 
apparent, nor significant, difference between the serum 
concentrations in their effect on pyrogen release by 
NHD tissue. 
The same study was performed with 11 samples of 
spleen tissue (Figure VII). Results for a first incubation 
alone, and for pyrogen release per incubation during two 
consecutive 24 hour incubations are presented. There is 
an apparent, but not statistically significant (p < .2), 
difference in pyrogen release during the first 24 hours 
incubation by spleen cells from HD patients, when incubated 
in the two concentrations of serum (Fig. Vila). Cells 
incubated in 30$ serum released less pyrogen than those 
incubated in 10$ serum. There is no apparent effect of 
incubation in 30$ serum as compared with 10$ serum on pyrogen 
release by the NHD spleen cells. 
When pyrogen release, per incubation, averaged over 
two incubations is examined, (Fig. Vllb), there is no 





serum concentrations on pyrogen release by spleen cells 
from either HD or NHD patients. 
Since it was felt that autologous serum might be 
more effective than homologous serum in suppressing 
pyrogen release from HD tissues, a subseries (six 
specimens) was selected in which only those spleens 
which had incubated in both high and low concentrations 
of autologous serum were included (Figure VTIc, d). Again 
there is an apparent but not significant (p<.2) difference 
in pyrogen release during a first incubation when cells 
from HD spleens were incubated in 30% as compared to 10% 
serum. There is no significant effect of varying serum 
concentration demonstrated in .the NHD group for the 
first incubation nor in either group if the pyrogen released 
on each of two incubations is averaged over both incubations. 

Figure Vis Effect of Serum Concentration on Pyrogen 
Release by Lymph Node Cells in vitro. 
Comparison of mean peak temperature elevations 
following injection of supernates from incubation of 
lymph node tissue in either 10% or 30% serum, during 
first or second 24 hour incubation. Data for both HD 































Figure Vila: Effect of Serum Concentration on Pyrogen 
Release by Spleen Cells in vitro s I. 
Comparison of mean peak temperature elevations 
following injection of supernates from incubation of 
spleen cells in either 10fo or 30^ serum, during the first 
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Figure Vllbi Effect of Serum Concentration on Pyrogen 
Release by Spleen Cells bn vitro; II. 
Comparison of mean peak, temperature elevations following 
injection of supernates, from incubation of spleen cells 
in either 10$ or 30$ serum during either a first or second 

























Figure Vile* Effect of Serum Concentration on Pyrogen 
Release by Spleen Cells in vitroa III, 
Comparison of mean peak temperature elevations folio 
ing injection of supernotes from incubation of spleen 
cells in either 10% or 2,0% autologous serum during a 
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Figure Vlld* Effect of Serum Concentration on Pyrogen 
Release by Spleen Cells .in vitro: IV. 
Comparison of mean peak temperature elevations 
following injection of supernates from incubation of 
spleen cells in either 10$ or autologous serum, 
during either a first or second 2b hour incubation, 
























IIB. Serum Studies: the effect of varied serum source 
upon spontaneous EP release by lymphoid tissue in 
vitro. 
In order to further investigate the possibility 
that a factor in the serum of Hodgkin's disease patients 
may suppress pyrogen production, and thus, perhaps, be 
responsible for preventing EP release in vivo, aliquots 
of cells from a single tissue were incubated in autologous 
serum, or in homologous normal 0- donor serum. Concentra¬ 
tions of 10-15$ or 30-35$ serum in TCM were both used, 
but in each autologous-homologous pair of incubations, the 
same concentration was employed. 
Again, all incubations for each tissue over two days 
were combined in determining the average pyrogen released 
during each incubation of the seven lymph node specimens 
(Figure VIII). HD lymph node cells incubated with auto¬ 
logous serum released significantly less pyrogen per 24 
hours of incubation, than did the same tissue incubated 
with homologous normal serum (p < .05). There is no 
significant difference between pyrogen release by lymph 
node cells in the NHD group when incubated with the two 
types of serum (p < .2). 




specimens, varying the type of serum did not alter 
release of pyrogen during the first 24 hour incubation 
(Figure IXa) or release, per incubation, averaged over 
two consecutive 24 hour incubations (Figure IXb). Since, 
as noted in Figure Vila, 30$ serum appears to suppress 
release of pyrogen by spleen cells in the HD group, 
during the first 24 hours, an effect of autologous vs. 
homologous serum might be more marked in a group of tissues 
incubated at this concentration. Consequently results of 
eleven experiments in which splsen cells from either HD 
or NHD patients had been incubated in both 30$ autologous 
and 30$ homologous normal serum during the first 24 hour 
incubation were analyzed (Figure IXc). Spleen cells from 
patients with HD, but not from patients in the NHD group, 
produced less pyrogen when incubated with 30$ autologous 
as compared to normal homologous serum, although the 
difference is not statistically significant (p K. .1). 
To look at these experimental results in a different 
way, comparison was made for each spleen cell preparation, 
between response to supernatant from incubation in 3Q$-auto- 
logous serum and in 30$ homologous normal serum, during the 
same period. If the mean peak temperature elevations dif¬ 
fered by greater than 0.15° C, the difference was presumed 




were considered equal. In experiments with six spleens 
from patients with HD, six comparisons could be made. 
In four, the incubation in homologous normal serum 
released more pyrogen; in two the responses were equal. 
In experiments with five spleens from NHD patients (2NHL, 
ZITP, 1 SLE) five comparisons could be made. In two 
cases more pyrogen was released by incubation in homo¬ 
logous serum; in one case by incubation in autologous 
serum. In two cases no difference was found. 

Figure VIII* Effect of Serum Source on Pyrogen Release 
by Lymph Node Cells in vitro. 
Comparison of mean peak temperature elevations fol¬ 
lowing injection of supernates from incubation of lymph 
node cells in either autologous (Auto) or normal homo¬ 
logous (Homo) serum, during either a first or second 24 






















Figure IXa: Effect of Serum Source on Pyrogen Release 
by Spleen Cells in vitroi I. 
Comparison of mean peak temperature elevations fol¬ 
lowing injection of supernates from incubation of spleen 
cells in either autologous or normal homologous serum, 
during a first incubation. Data are presented for both 































Figure* JXb* Effect of Serum Source on Pyrogen Release 
by Spleen Cells in vitro: II. 
Comparison of mean peak temperature elevations 
following injection of supernates from incubation of 
spleen cells in either autologous or normal homologous 
serum, during either a first or a second 24 hour incuba¬ 

































Figure IX c s Effect of Serum Source on Pyrogen Release 
by Spleen Cells in vitroi III. 
Comparison of mean peak temperature elevations fol¬ 
lowing injection of supernates from incubation of spleen 
cells in either autologous or JOfo normal homologous 
serum, during a first 24 hour incubation. Data are pre¬ 
sented for both HD and NHD groups. 





III. Endogenous pyrogen release in vitro by a combined 
population of tissue lymphocytes and circulating 
blood leukocytes. 
In order to examine the effect of lymphocytes from 
these tissues on induction of pyrogen release by cells 
capable of pyrogen release, but obtained in an inactive 
state, tissue lymphocytes were incubated together with 
blood leukocytes. 
Since the available lymph node tissue was small in 
amount, and since its composition was, in all cases but one, 
under five per cent polymorphonuclear leukoyctes, it was 
decided to use lymph node cells obtained directly from 
teased or minced lymph nodes as a lymphocyte source. To 
obtain spleen lymphocytes, a glass wool column was used, to 
which the phagocytic cells were allowed to stick (see 
Materials and Methods). The eluate cells were predominantly 
small lymphocytes (average of 89$ in 17 experiments). The 
majority of the remaining 11% were large mononuclear cells, 
some of which may have been large lymphocytes rather than 
tissue monocytes, and, therefore, non-pyrogen producing. 
Lymph node cells and spleen column eluate cells were 
then incubated with blood leukocytes from normal donors or 
from patients. Control suspensions of tissue lymphocytes 





Supernates obtained after successive 24 hour incubations 
were assayed for pyrogen. A "positive" response required 
that the supernate from the incubation of the two cell 
populations together contain sufficient pyrogen to produce 
a mean peak temperature elevation greater than 0.3° C and 
greater than the mean peak temperature elevations of each 
of the control populations summed. When a supernate from 
an incubation containing either tissue lymphocytes or blood 
leukocytes alone produced sufficient pyrogen to produce a 
mean peak temperature elevation greater than 0.3° C, that 
experiment was excluded from the series, since induction of 
pyrogen release could not be determined in that case. 
The results of the experiments with lymphocytes from 
spleen are presented in Table II. Whe«i spleens from HD 
patients were used, there were four positives in seven 
experiments. When the spleens were from patients in the NHD 
group, there was only one positive of 10. This single posi¬ 
tive occurred with cells from the spleen that had ruptured 
two days preoperatively. The difference between the results 
in the two groups is significantly different by chi square 
(p K .05). There is no significant difference in the numbers 
of cells other than small lymphocytes between the two groups. 
The observation that there is a significant difference 
between the activity of the two populations of lymphocytes 








non-specific stimulus in these incubations. This 
possibility was further explored by incubating normal 
blood leukocytes with eluate from the column in the 
absence of spleen cells; no pyrogen release occurred. To 
further assure that the lymphocyte suspensions were not 
the source of the pyrogen, seven experiments were performed 
O 
in which 1 x 10° cells from the column were incubated with 
staphylococci, to provide a phagocytic stimulus, and in 
no case did pyrogen release occur. Furthermore, a positive 
response was never obtained by injection of the supernate 
from the control incubation of the column lymphocytes alone. 
When lymph node lymphocytes were studies in this system 
(Table III) there were three "positives" and no negatives 
in experiments using lymph nodes from patients with Hodg¬ 
kin's disease. There were only 3 positives out of nine 
experiments using lymph nodes from patients in the other 
groups (two of four positive in the NHL group, one of one 
in the reactive group, none of four positive in the meta¬ 
static carcinoma group). The difference between the results 
in the HD and NHD groups is significant by chi square. 
(p K 0.02). There is no significant difference between the 
two groups with respect to percentage of cells other than 
small lymphocytes amongst the lymph node cells (14±6% compared 
with 24±l8$). Two experiments were excluded, one each from 






sufficient pyrogen, incubated alone, at the dosage 
used for incubation with blood leukocytes, to inter¬ 
fere with the interpretation of results from the 
combined incubation. 
, 
Xable II:Pyrogen release in incubation mixtures 
containing spleen lymphocytes and 







HD 4 ? 57 
NED 1 9 10 10 
p<.05 by chi square 
* Mean peak temperature elevation >0*3°C. See text for 
explanation. 

Table III: Pyrogen release in incubation mixtures 
containing lymph node cells and 
blood leukocytes1. 
Pyrogen Release 





HD 3 0 3 100 
HKD 3 6 9 33 
p<.02 by chi square 





These results, like those of the earlier series of 
Bodel (15, 16) show that spleen tissue from patients with 
Hodgkin’s disease releases pyrogen spontaneously in vitro, 
and that this pyrogen release continues for at least 48 
hours. When assayed in rabbits, the pyrogen behaves, like 
an endogenous pyrogen rather than endotoxin, since it causes 
a prompt, early fever with onset within fifteen minutes and 
peak temperature elevation within 90 minutes. Also, 
repeated injections of tissue pyrogen three times per day for 
four days, continues to cause undiminished pyrogenic responses. 
Spleen cells from patients with Hodgkin’s disease 
release significantly more pyrogen during a first 24 hour 
incubation than do spleen cells from patients with other 
conditions requiring splenectomy, including non-Hodgkin’s 
lymphoma. By the second day, pyrogen release between the 
two groups is comparable. 
Because pyrogen release continues for two days in 
vitro, and increases in amount over that period, it is 
likely that the pyrogen releasing cells are spleen mono¬ 
cytes. Polymorphonuclear leukocytes, unlike monocytes, 
release pyrogen only 12-16 hours after a single activating 
stimulus (17). However, it is possible that pyrogen 




activation of populations of polymorphonuclear leukocytes, 
each population active for only 12-16 hours. 
It is unclear exactly what spontaneous endogenous 
pyrogen release in vitro represents, especially since 
pyrogen release by all groups of tissue was similar after 
24 hours. It may indicate a previously altered state of 
the cells or it may result from non-specific activation by 
some process in the surgical or laboratory handling of the 
tissue. Clearly, if it is the latter, then there is some 
difference in the response of the HD and NHD groups to this 
activation stimulus. This difference could be one of acti¬ 
vation threshold, degree of res pnse to identical stimuli, 
or speed of response. If it represents a previously altered 
state of the cell, that alteration may be actual in vivo 
pyrogen release, there must be some in vivo modification of 
its effect, since none of the patients in the HD group were 
febrile at the time of, or shortly prior to surgery. This 
modification might result from EP inactivation in the circu¬ 
lation (such as by protein binding or enzymatic degradation), 
prevention of EP effect upon the thermoregulatory neurons 
of the hypothalmus, or prevention of fever by interruption 
of the efferent limb of the termperature regulating mechanism, 
such as by altered function of the autonomic nervous system. 
The observed spontaneous EP release may also result 




disease-specific difference in cell behavior between the 
two groups of tissues. For instance, release of pyrogen 
after the first 24 hours may be due to nonspecific activation, 
whereas the early response, seen in tissues of the HD group, 
may be due to a specific activating condition present in 
the one, but not the other group. The similar early 
release of EP from the spleen tissue of the patient with 
traumatic rupture and inflammation, a situation that seems 
likely to have led to in vivo cell activation, supports 
this conclusion. 
Only 20% of the spleens from the HD group were "positive" 
for evidence of the disease on histological examination. 
This group was too small to allow division of the HD group 
into two subgroups (one with, and one without pathological 
involvement) for analysis. Previous work by Bodel, however, 
has shown no correlation between in vitro pyrogen release 
and histological involvement (16). This suggests that if 
the observed pyrogen release is, at least in part, disease 
specific, it either does not require pathological involve¬ 
ment of the tissue by the disease process, or it occurs 
in the tissue without leaving the histological evidence 
which we recognize as Hodgkin's disease. An example that 
such alterations take place is the demonstration of a HD 
associated antigen in pathologically "negative" spleens from 






The results of these experiments, then,suggest that, 
in Hodgkin’s disease, there may be a relation between altered 
production of EP in vitro and a high frequency of fever iji vivo. 
In a general way, they support the hypothesis that EP 
release from lymphoid tissue might be the mechanism for the 
fever of Hodgkin’s disease. However, they do not explain 
the activation mechanism for EP release in patients with 
Hodgkin's disease. 
Unlike the results in Bodel's series (16), there is 
no evidence here that lymph node tissue from patients with 
Hodgkin’s disease releases significantly more :pyrogen upon 
in vitro incubation than does nodal tissue from patients 
with other conditions requiring lymph node biopsy. This 
suggests that the lymph node is not a major site of pyrogen- 
producing cells in this disease. Further evidence for this 
conclusion is the finding that the pyrogen content of the 
supernates incubated with lymph node cells from two patients 
with febrile histories is not significantly different from 
that of supernates in the group as a whole (mean peak temp¬ 
erature elevation of 0.20° C compared with 0.29° C). This 
does not exclude a role for lymph node cells in the process 
of pyrogen production as activators of other cells. It 
probably does indicate that few cells capable of pyrogen 
production are present in the nodes. However, because the 





pyrogen release when lymph node cells from HD patients are 
incubated in autologous serum and in 30# serum, the capacity 
for EP release may have been masked, in this series, by the 
use of both autologous serum and 30% concentration in some 
incubations. 
Studies of the effect of serum on pyrogen release 
were undertaken to look for factors which might modify the 
capacity of tissue cells for pyrogen release. Such a 
factor might help to explain the lack of correlation between 
in vitro EP release and clinical fever, reported in Bodel's 
series. Clearly, cells in vivo are exposed to the patient’s 
serum at a concentration greater than the 10-15# used in 
our routine incubations. It was hypothesized that a factor 
might be present in the patient’s serum which at most times 
prevents the cells’ capacity for EP release from becoming 
manifest in vivo. Failure of this suppressive mechanism 
might then lead to a state of fever. 
Two studies were set up, one in which serum concentra¬ 
tion was either 10 or 30#, and the other in which the serum 
used was either autologous or normal homologous. In each 
study an effect of changes in serum was more apparent when 
lymph node, rather than spleen, tissue was used. This may 
be because their lesser pyrogen release is more easily in¬ 
hibited. Alternatively, it may be that only pyrogen release 
by mononuclear cells is inhibited by a serum factor, and 








both mononuclear and polymorphonuclear cells. However the 
results, in both tissues, consistently support the conclusion 
that incubation in 30% serum concentration, or autologous 
serum, leads to less pyrogen release by cells from Hodgkin's 
disease patients, as compared with incubation in 10% serum 
or with normal homologous serum. No such effect was observed 
on pyrogen release by cells from nodes or spleen of patients 
with non-Hodgkin's diseases. This finding suggests that the 
observed suppressive effect on tissue from HD patients is 
a disease-specific one. 
Because the number of specimens is small and the 
differences are not all statistically significant, further 
studies will be required to establish this finding con¬ 
clusively. Howearer, these results fit with the hypothesis, 
outlined above, that a factor present in the serum of 
patients with HD suppresses pyrogen release by spleen and 
lymph node cells from these patients. Such a factor 
would be another example of host response to his tumor, 
others of which include blocking factor in malignant melanoma 
and an anti-blast transformation factor in Hodgkin's 
disease (86). Perhaps if the series could be extended, the 
results would become significant, or in the case of the 
serum concentration study, if even higher concentrations 
of serum were used, the effect might become more clear cut. 
The results are encouraging and suggest that further experi¬ 









It is not clear however, why, when serum concentrations 
were varied, the suppressive effect of the higher serum 
concentration on s jLeen cells from patients with HD is not 
maintained when the results of incubation during each 24 
hour period are considered together. This may reflect a 
difference in the means by which th € HD spleen cells are being 
activated on the two days. As discussed above, spontaneous 
pyrogen release by the spleen cells may be partially in 
response to non-specific activation due to handling, and 
partly in response to disease-specific activating mechanisms. 
The serum factor may have an effect only on the disease- 
specific mechanism, presumed to be acting during the first 
day, and not on non-specific activation. 
If the demonstration of spontaneous endogenous pyrogen 
release in vitro by spleen cells from Hodgkin’s disease 
patients is not simply an artifact of handling, we must 
consider by what mechanism these cells have been altered 
in vivo. It is possible that, if the disease is caused by 
a virus, infection with the agent may activate the cell to 
pyrogen production. Parainfluenza virus is known to cause 
EP release from blood leukocytes in vitro, for instance (6). 
Another possible etiology for Hodgkin’s disease, proposed 
by Vianna, et al, suggests that there is a virus infection 
in the barrier lymph nodes of the oropharynx or gut, which 
does not reach those lymph nodes which become what we recog¬ 
nize histologically as being involved by the disease, but 
. 





which seeds antigen-antibody complexes to the draining 
lymphoid tissue (98). The disease is presumed to be a re¬ 
sponse to the antigen-antibody complexes. Antigen-antibody 
complexes have also been shown to be activators of EP 
release in vivo and in vitro (85). 
Another possibility is that the activator in these 
tissues is a lymphokine. In the hypothesized patogenesis 
of Hodgkin’s disease, proposed by Order and Heilman, and 
discussed previously, a cell-mediated immune response occurs 
in the involved tissue. Activated T lymphocytes are now 
known to produce a number of non-antibody products which 
are known as lymphokines (37). These include a mitogenic 
factor, a lymphocytotoxin, and a migration inhibiting factor 
for macrophages. There is some recent evidence that a 
lymphokine can activate blood cells to produce endogenous 
pyrogen. 
In our experiments, lymphocytes from the spleens and 
lymph nodes were incubated together with circulating leuko¬ 
cytes to look for evidence of such a substance. In the 
seven incubations in which spleen lymphocytes from patients 
with Hodgkin’s disease were combined with leukocytes, pyrogen 
release occurred in four instances. Similar release occurred 
in all three incubations in which lymphocytes from lymph 
nodes of patients with Hodgkin’s disease were used. Both 





lymphocytes from tissues of patients with other diseases 
were used, where pyrogen release occurred in only one of 
ten ex jeriments using spleen cells and three of nine using 
lymph node cells. 
These results provide evidence for some kind of inter¬ 
action between the two cell populations, which results in 
pyrogen release by one or both of them. The "lymphocyte 
population" was about 90$ small lymphocytes, which are non¬ 
pyrogen producing cells; these preparations incubated alone 
or with a phagocytic stimulus, never released pyrogen. 
Thus even the 10$ of cells which were possible pyrogen 
producing cells by microscopic examination were probably 
not pyrogen producing in these experiments. Consequently, 
it appears that the blood leukocytes are the source of 
the measured pyrogen. Since the same blood leukocytes did 
not release pyrogen when incubated under the same conditions 
without lymphocytes, it appears that some inter-action 
between the two cell populations was responsible for their 
activation. 
Whether the important aspect of the inter-action is 
one specific to the action of lymphocytes from patients with 
Hodgkin’s disease, or a non-disease-related action is un¬ 
clear. Evidence against its being non-specific is the 
significant difference between the results of the experiments 
using lymphocytes from tissues of patients with HD and NHD. 
, 9 
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Additional evidence against its being due to some artifact 
of the column procedure, ifa experiments with spleen tissue, 
such as wool particles which act as phagocytic stimuli to 
the leukocytes, is that an acellular column eluate, 
incubated with blood leukocytes, does not cause pyrogen 
release. Another non-disease-specific cell inter-action 
may be an immune inter-action between the two cell pop¬ 
ulations obtained from different individuals, in those 
cases in which the leukocytes were from a normal donor 
rather than from the patient himself. However, in the 
experiments with spleen cells, both positive and negative 
experiements, in both HD and NHD groups, contained patient 
lymphocytes and normal leukocytes. Thus, immune inter¬ 
action, even if present, cannot account for the difference 
between the results of experiments in which patient blood 
cells or normal blood cells were used. However, further 
studies of the mixed lymphocyte reaction will be needed to 
clearly resolve this question. 
The evidence, at present, favors a disease-specific ef¬ 
fect since induction of pyrogen release by blood leukocytes 
occurs more frequently when lymphocytes from HD patients 
are used. One explanation for a specific disease-related 
inter-action would be release of a lymphokine by altered 
lymphocytes present in HD patients. The results of these 
experiments do not however, :pirove such a conclusion. Further 
- 
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supporting evidence would be the demonstration of pyrogen 
release by blood leukocytes after incubation with the 
supernate of a previous incubation of the lymphocytes alone. 
Whether a lymphokine is, in fact, the mechanism for 
the demonstrated lymphocyte activity on blood leukocytes, 
spontaneous endogenous pyrogen release by spleen cells 
from Hodgkin's disease patients in vitro may result from 
the action of altered lymphocytes on tissue pyrogen- 
producing cells. This alteration may be due to a reaction 
to an antigen in the tissue. A Hodgkin's disease- 
associated antigen has been observed in both pathologically 
diseased and apparently normal spleens from patients with 
Hodgkin's disease (75, 77). Thus, the findings of 
altered lymphocyte function, demonstrated in this in vitro 
system, is consistent with, and would be required by, 
the hypothesis for the patogenesis of Hodgkin's disease 
proposed by Order and Heilman. 

SUMMARY 
Lymph node and spleen cells from patients with 
Hodgkin’s disease and various other disorders requiring 
splenectomy or lymph node biopsy were incubated in tissue 
culture medium in vitro. On the first day of incubation, 
spleen cells from patients with Hodgkin's disease released 
significantly more pyrogen than those from patients with 
non-Hodgkin’s disease. Pyrogen release during a second 
24 hour incubation was comparable in the two groups. There 
was no significant difference between the pyrogen release 
by the two groups of lymph nodes during either a first or 
second 24 hour incubation. 
The effect of changing serum concentration in the 
incubation media from 10 to 30% was studies in this system. 
Lymph node cells from patients with Hodgkin's disease in¬ 
cubated in 30% serum released apparently, but not signifi¬ 
cantly, less pyrogen per day than the same cells incubated 
in 10% serum. Pyrogen release by cells from patients in the 
non-Hogkin’s disease group was not affected by the different 
serum concentrations. Pyrogen release during a first in¬ 
cubation, by spleen cells from patients with Hodgkin’s 
disease was apparently less in 30% serum than in 10% serum, 
but this effect was not seen when results of both the first 
and second incubations were included together. No effect of 
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serum concentration was observed on spleen cells from 
patients with other diseases. 
Different sera, either autologous or normal 0- 
homologous serum, were compared for effect on pyrogen 
release i_n vitro. Lymph node cells from patients with 
Hodgkin's disease incubated in autologous serum released 
less pyrogen per day, over two days, than did lymph node 
cells from the same patients incubated in homologous 0- 
serum. The different sera did not affect pyrogen release 
by lymph node cells from the non-Hodgkin's disease patients 
differently. Pyrogen release by spleen cells, whether 
from Hodgkin's or non-Hodgkin's patients, was not signi¬ 
ficantly different when homologous rather than autologous 
serum was used. In the experiments in which spleen cells 
from patients with Hodgkin's disease were incubated in 
30% autologous or 30% homologous serum, cells incubated 
in autologous but not homologous serum, released apparently, 
but not significantly, less pyrogen during a first 24 hour 
incubation. 
In the final group of experiments, spleen or lymph 
node lymphocytes were incubated with circulating blood 
leukocytes. Four of seven mixtures released pyrogen when 
lymphocytes from spleens of Hodgkin's disease patients 
were used. In only one of ten experiements was pyrogen 
released when spleen lymphocytes from patients with non- 
« ' 
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Hodgkin's disease were used. The difference is significant. 
When lymph node cells were used, all three incubation mix¬ 
tures containing cells from patients with Hodgkin's disease 
released pyrogen, whereas only three of nine released pyrogen 
when lymph node cells were from patients with non-Hodgkin’s 
disease. Th tdifference is significant. 
Lymphoid tissue, from patients with Hodgkin's disease 
has been shown to be capable of spontaneous and prolonged 
endogenous pyrogen release ini vitro. Some evidence has 
been found suggesting that serum factors may modify this 
capacity of tissue cells fro EP release in vitro. Lympho¬ 
cyte preparations from these tissues appeared to have the 
capacity to activate normal blood leukocytes to release 
pyrogen. These results suggest that the mechanism for 
the spontaneous release of EP by spleen preparations may 
involve the action of tissue lymphocytes on cells capable 
of pyrogen release, as by elaboration of a lymphokine. 
They further suggest that fever in Hodgkin's disease may 
result from the abnormal behavior of lymphoid tissue cells. 
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